HLA-B8 association with late-stage melanoma – an immunological lesson?

• Main Authors: Andersen Mads, Berger Thomas, Trefzer Uwe, Fensterle Joachim, Ugurel Selma, Becker Jürgen C
• Format: Article
• Language: English
• Published: BMC 2006-03-01
• Series: BMC Medicine
• Online Access: http://www.biomedcentral.com/1741-7015/4/5

<p>Abstract</p> <p>Background</p> <p>Differences in HLA allele frequencies between the diseased and healthy populations may signify efficient immune responses, a notion that has been successfully tested for infectious diseases or for association with genetic elements involved in a distinct type of immunity. This retrospective study is intended to detect differences in MHC class I carrier frequencies of advanced melanoma patients compared to healthy bone marrow donors.</p> <p>Methods</p> <p>The HLA-A and -B carrier frequencies of 748 stage IV melanoma patients retrieved from serotyping at 6 different centers in Germany were compared using a chi-square test to 13,386 fully HLA typed bone marrow donors registered in the German national bone marrow donor registry.</p> <p>Results</p> <p>The comparison of HLA carrier frequencies in advanced cancer patients with healthy bone marrow donors revealed a significant decrease in HLA-B8 carrier frequencies, which was also apparent in patients with advanced disease compared to patients with loco-regional disease.</p> <p>Conclusion</p> <p>The data suggest that protective immune responses restricted to distinct MHC class I molecules may be operational in a subset of melanoma patients, which is the prerequisite for a large scale screen for the corresponding epitopes. Alternatively, the known association of the ancestral haplotype HLA-A1, -B8 and -DR3 with genetic elements such as distinct TNF-α alleles might have a protective effect on disease progression. In any case, identification of the cause of protection within this patient subset might lead to a significant improvement in the efficacy of current immunotherapeutic approaches.</p>